PleoPharma’s PP-01 Shows Promise in Treating Cannabis Withdrawal Syndrome
PHOENIXVILLE, PA — PleoPharma, Inc. has announced promising results from a Phase 2b study evaluating its leading drug candidate, PP-01, intended for mitigating Cannabis Withdrawal Syndrome. Conducted across 22 US addiction …
PleoPharma’s PP-01 Shows Promise in Treating Cannabis Withdrawal Syndrome Read More